FDA Approves Pfizer’s RSV Vaccine for Older Adults

Pfizer's New York headquarters in the Manhattan borough of New York City on Nov. 9, 2020. Carlo Allegri/Reuters

The Food and Drug Administration (FDA) has approved Pfizer’s vaccine, Abrysvo, which protects adults 60 and older from the respiratory syncytial virus (RSV), Pfizer announced on Wednesday.

The approval makes Abrysvo the second RSV vaccine available for the common virus. On May 3, the agency approved GSK’s Arexvy, the world’s first RSV vaccine for adults 60 and older.